Biotechs fight fears of ‘antibiotic apocalypse’
02 September 2019
Market failure gives little incentive to develop new drugs as antimicrobial resistance grows.
Carb-X and Repair Impact Fund to fund R&D of novel antibiotics. However, Pharma needs to take over later in the development.
Further reading: Financial Times
Author(s): Clive Cookson
Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
